Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Esperion Theraptc (NQ: ESPR )

6.360 -0.140 (-2.15%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,164,684
Open 6.500
Bid (Size) 6.370 (52)
Ask (Size) 6.600 (10)
Prev. Close 6.500
Today's Range 6.350 - 6.630
52wk Range 3.280 - 8.870
Shares Outstanding 28,277,493
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500
NASCAR Champion Brad Keselowski to Run No. 6 NEXLIZET (bempedoic acid and ezetimibe) Ford in Famed Daytona 500 
From Esperion Therapeutics, Inc.
Via Globe NewsWire
Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results
From Esperion Therapeutics, Inc.
Via Globe NewsWire

Performance

YTD
+8.90%
+8.90%
1 Month
+8.90%
+8.90%
3 Month
-23.19%
-23.19%
6 Month
+8.35%
+8.35%
1 Year
+48.25%
+48.25%

More News

Read More
Top Picks For 2023: Esperion
Via Talk Markets
CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC)
From Esperion Therapeutics, Inc.
Via Globe NewsWire
Recap: Esperion Therapeutics Q3 Earnings
Via Benzinga
Esperion Therapeutics: Q2 Earnings Insights
Via Benzinga
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via Globe NewsWire
Esperion to Participate in January Investor Meetings
From Esperion Therapeutics, Inc.
Via Globe NewsWire
Esperion Therapeutics Reports Sooner Than Expected Positive Data From Nexletol Trial
Via Benzinga
Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint
From Esperion Therapeutics, Inc.
Via Globe NewsWire
Esperion Appoints Ben Halladay Chief Financial Officer
From Esperion Therapeutics, Inc.
Via Globe NewsWire
Esperion Therapeutics's Return On Capital Employed Insights
Via Benzinga
Esperion Virtual Research & Development Day to Highlight Pipeline Programs and Scientific Focus
From Esperion Therapeutics, Inc.
Via Globe NewsWire
Esperion to Participate in Jefferies London Healthcare Conference
From Esperion Therapeutics, Inc.
Via Globe NewsWire
Esperion Reports Third Quarter 2022 Financial Results and Provides Company Update
From Esperion Therapeutics, Inc.
Via Globe NewsWire
Esperion Hosting Virtual Research & Development Day
From Esperion Therapeutics, Inc.
Via Globe NewsWire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via Globe NewsWire
Esperion to Report Third Quarter 2022 Financial Results November 1, 2022
From Esperion Therapeutics, Inc.
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022
Via Benzinga
U.S. Stock Futures Gain Ahead of Services PMI; Crude Oil Drops Over 1%
Via Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2022
Via Benzinga
A Peek Into The Markets: US Stock Futures Down Following Wednesday's Surge
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.